SG11201402711SA - Compositions and methods for prostate cancer analysis - Google Patents

Compositions and methods for prostate cancer analysis

Info

Publication number
SG11201402711SA
SG11201402711SA SG11201402711SA SG11201402711SA SG11201402711SA SG 11201402711S A SG11201402711S A SG 11201402711SA SG 11201402711S A SG11201402711S A SG 11201402711SA SG 11201402711S A SG11201402711S A SG 11201402711SA SG 11201402711S A SG11201402711S A SG 11201402711SA
Authority
SG
Singapore
Prior art keywords
compositions
methods
prostate cancer
cancer analysis
analysis
Prior art date
Application number
SG11201402711SA
Inventor
Siminder Atwal
Jo-Anne Hongo
Mark Lackner
Elizabeth Punnoose
Bonnee Rubinfeld
Rajesh Vij
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161629886P priority Critical
Priority to US201261703099P priority
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to PCT/US2012/066998 priority patent/WO2013082249A2/en
Publication of SG11201402711SA publication Critical patent/SG11201402711SA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y116/00Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048Protein-tyrosine-phosphatase (3.1.3.48)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4742Keratin; Cytokeratin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90287Oxidoreductases (1.) oxidising metal ions (1.16)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis
SG11201402711SA 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis SG11201402711SA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161629886P true 2011-11-29 2011-11-29
US201261703099P true 2012-09-19 2012-09-19
PCT/US2012/066998 WO2013082249A2 (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis

Publications (1)

Publication Number Publication Date
SG11201402711SA true SG11201402711SA (en) 2014-06-27

Family

ID=47324459

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402711SA SG11201402711SA (en) 2011-11-29 2012-11-29 Compositions and methods for prostate cancer analysis

Country Status (15)

Country Link
US (2) US20130143237A1 (en)
EP (1) EP2786151B1 (en)
JP (1) JP6219304B2 (en)
KR (1) KR101951514B1 (en)
CN (1) CN104067127A (en)
AR (1) AR089028A1 (en)
AU (1) AU2012345926A1 (en)
BR (1) BR112014012882A2 (en)
CA (1) CA2854042A1 (en)
IL (1) IL232466A (en)
MX (1) MX350807B (en)
RU (1) RU2641968C2 (en)
SG (1) SG11201402711SA (en)
WO (1) WO2013082249A2 (en)
ZA (1) ZA201403110B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646661A (en) * 2014-03-24 2016-06-08 朱育盼 Short-chain polypeptides PCP2 capable of being specifically bound to prostate cancer cells and application of short-chain polypeptides PCP2
CN108064343A (en) * 2015-04-21 2018-05-22 基因泰克公司 Compositions and methods for prostate cancer analysis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific, oligo, mono- and oligovalent antikoerperkonstrukte, their production and use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
CA2320418C (en) 1998-02-12 2008-06-17 Leon W.M.M. Terstappen Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
IL129299D0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy A process for the regulation of transcription of foreign genes in the presence of nitrogen
WO2003065042A1 (en) 2001-02-16 2003-08-07 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7219016B2 (en) * 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
SI1742966T1 (en) * 2004-04-22 2014-03-31 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR20140116546A (en) * 2006-10-27 2014-10-02 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
JP5394246B2 (en) * 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド Antibodies and immunoconjugates and methods of using these
CA2668961A1 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of Michigan Spink1 as a prostate cancer marker and uses thereof
US8445225B2 (en) * 2008-09-05 2013-05-21 The Scripps Research Institute Methods for the detection of circulating tumor cells
JP5975983B2 (en) 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ, インコーポレイテッド A method for treating a solid tumor

Also Published As

Publication number Publication date
IL232466A (en) 2017-10-31
RU2641968C2 (en) 2018-01-23
CN104067127A (en) 2014-09-24
KR101951514B1 (en) 2019-02-22
WO2013082249A2 (en) 2013-06-06
JP2015507175A (en) 2015-03-05
MX350807B (en) 2017-09-20
EP2786151A2 (en) 2014-10-08
BR112014012882A2 (en) 2017-06-13
ZA201403110B (en) 2017-06-28
MX2014006187A (en) 2014-06-23
EP2786151B1 (en) 2019-07-03
US9632091B2 (en) 2017-04-25
JP6219304B2 (en) 2017-10-25
KR20140100544A (en) 2014-08-14
WO2013082249A3 (en) 2013-10-10
AR089028A1 (en) 2014-07-23
IL232466D0 (en) 2014-06-30
AU2012345926A1 (en) 2014-05-29
RU2014126358A (en) 2016-01-27
CA2854042A1 (en) 2013-06-06
US20160274116A1 (en) 2016-09-22
US20130143237A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
EP2812355A4 (en) Compositions and methods for using csf1r inhibitors
IL220939D0 (en) Compounds and methods
EP2700061A4 (en) Systems and methods for analyzing energy usage
ZA201306944B (en) Individualized vaccines for cancer
HK1203566A1 (en) Methods and compositions for treating huntingtons disease
EP2904106A4 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
EP2702175A4 (en) Methods and compositions for nucleic acid analysis
IL238047D0 (en) Compositions and methods for immunotherapy
PL3222266T3 (en) Compositions and methods for targeted thermomodulation
TWI600427B (en) Methods of treating cancer
EP2655334A4 (en) Compositions and methods useful for treating diseases
EP2721179A4 (en) Biomarker compositions and methods
EP2760452A4 (en) Methods of treating cancer
EP2742154A4 (en) Biomarker compositions and methods
EP2858722A4 (en) Compostions and methods for cancer immunotherapy
TWI544682B (en) Wideband antenna and methods
EP2823306A4 (en) Biomarker compositions and methods
IL238254D0 (en) Methods of treating cancer
EP2751292A4 (en) Methods and compositions for detecting cancer based on mirna expression profiles
PL2814959T3 (en) Compositions and methods for accurately identifying mutations
GB201010196D0 (en) Methods
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
EP2589391A4 (en) Method for treating and diagnosing cancer by using cell-derived microvesicles
EP2523664A4 (en) Compounds and methods
EP2665521A4 (en) Compositions and methods for treating cancer